Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Trial Timeline
Nov 1, 2006 → Oct 1, 2008
NCT ID
NCT00381173About Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) is a phase 1 stage product being developed by Eisai for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00381173. Target conditions include Breast Cancer, Ovarian Cancer, Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00381173 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer